A case of nasal septal perforation secondary to systemic bevacizumab therapy for ovarian cancer is reported. Bevacizumab is a vascular endothelial growth factor A (VEGF-A) inhibitor that is becoming more widely utilized in the oncologic community. There is only one prior report of septal perforation secondary to bevacizumab in the Otolaryngology specific literature. The purpose of this report is: 1) to raise awareness and discuss the literature surrounding the sinonasal complications of bevacizumab and 2) provide workup and treatment recommendations based on the sum of the available literature.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2k67NdV
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
We are excited to share with you the newest dentistry and patient safety editions recently added to STAT!Ref. As a reminder, all STAT!Ref c...
-
Abstract Sexual dimorphism in the human respiratory system has been previously reported at the skeletal (cranial and thoracic) level, but ...
-
Abstract The effects of oxygen addition on a helium-based flowing atmospheric pressure afterglow (FAPA) ionization source are explored. Sm...
-
Objective Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. Ho...
-
2016-12-10T02-17-59Z Source: Indo American Journal of Pharmaceutical Research M.R. Pradeep Kumar*, Shrinivas D. Joshi . With an objecti...
-
http://ift.tt/2svTdo9
-
The evaluation of mineral resources development efficiency is a typical multicriteria decision-making issue. Meanwhile, due to the limited e...
-
Photochem. Photobiol. Sci. , 2018, Accepted Manuscript DOI : 10.1039/C7PP00350A, Paper Yan Xie, Jianrong Gao, Shaozheng Zhang, Liang Wu F...
-
Background: Inferring the topology of gene regulatory networks (GRNs) from microarray gene expression data has many potential applications, ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου